

REMARKS

The claims are finally rejected as lacking enablement under 35 USC § 112, first paragraph. In order to facilitate examination of the claims, the claims are amended herein so that they conform with the actual examples or claim subject matter that the examiner acknowledges in the office action is a reasonable extension of the examples. The claims have been amended by eliminating some of the selections for R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup>. The definition of R<sup>3</sup> has also been expanded by adding imidazolidinone to the list of heterocycles. This corresponds to R<sup>3</sup> in Example 37. No new matter has been introduced.

The examiner has also objected to claims 8-12 and 18 for depending on a later numbered claim. This objection is traversed, because amending claims so that lower numbered claims depend on higher numbered claims is a commonly used tool for amending claims without rewriting all of the claims when a new parent claim is added.


CONCLUSION

All of the grounds for rejection have been overcome. It is respectfully submitted that the claims are in condition for allowance. Such allowance is earnestly solicited. If the examiner wishes to discuss any matter relating to this application, he is invited to telephone the undersigned attorney at the number below.

A fee is not believed to be required with this timely response. If any fee is required, the fee may be charged to Merck Deposit Account No. 13-2755.

Respectfully submitted,

By

  
James L. McGinnis  
Reg. No. 34,387  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0641

Date: October 6, 2008